Research programme: cancer immunotherapies - Formation Biologics

Drug Profile

Research programme: cancer immunotherapies - Formation Biologics

Alternative Names: AVID-200

Latest Information Update: 04 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AvidBiologics
  • Developer Formation Biologics; National Research Council Canada
  • Class Antibodies; Drug conjugates; Immunoconjugates; Immunotherapies
  • Mechanism of Action Epidermal growth factor receptor modulators; Immunomodulators; Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer; Head and neck cancer; Solid tumours

Most Recent Events

  • 29 Nov 2016 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
  • 29 Nov 2016 Preclinical trials in Head and neck cancer in Canada (Parenteral) before November 2016
  • 29 Nov 2016 Preclinical development for solid tumours is still ongoing in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top